POWELL MICHAEL 4

Accession 0000899243-20-022200

CIK 0001651431other

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 9:04 PM ET

Size

20.0 KB

Accession

0000899243-20-022200

Form 4

Period: 2020-08-11

10% Owner

Transactions

Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total(indirect: See footnote)
→ Common Stock (1,671,771 underlying)
Purchase
Common Stock
2020-08-11$15.00/sh+133,333$1,999,995→ 3,606,707 total(indirect: See footnote)
Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total(indirect: See footnote)
→ Common Stock (1,314,165 underlying)
Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total(indirect: See footnote)
→ Common Stock (487,438 underlying)
Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total(indirect: See footnote)

10% Owner

Transactions

Purchase
Common Stock
2020-08-11$15.00/sh+133,333$1,999,995→ 3,606,707 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total(indirect: See footnote)
→ Common Stock (1,671,771 underlying)
Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total(indirect: See footnote)
Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total(indirect: See footnote)
→ Common Stock (1,314,165 underlying)
Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total(indirect: See footnote)
→ Common Stock (487,438 underlying)

Director10% Owner

Transactions

Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total(indirect: See footnote)
→ Common Stock (1,671,771 underlying)
Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total(indirect: See footnote)
→ Common Stock (1,314,165 underlying)
Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total(indirect: See footnote)
→ Common Stock (487,438 underlying)
Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total(indirect: See footnote)
Purchase
Common Stock
2020-08-11$15.00/sh+133,333$1,999,995→ 3,606,707 total(indirect: See footnote)

10% Owner

Transactions

Purchase
Common Stock
2020-08-11$15.00/sh+133,333$1,999,995→ 3,606,707 total(indirect: See footnote)
Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total(indirect: See footnote)
→ Common Stock (1,314,165 underlying)
Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total(indirect: See footnote)
→ Common Stock (487,438 underlying)
Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total(indirect: See footnote)
→ Common Stock (1,671,771 underlying)

Footnotes (3)

[F1]The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
[F2]The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
[F3]The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.

Documents

1 file

Checkmate Pharmaceuticals, Inc.

CIK 0001651431

Entity typeother